AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 311 min read$TNXP

LEDERMAN SETH purchased $28K of TNXP (indirect holdings)

LEDERMAN SETH (Chief Executive Officer) purchased 2,000 indirectly-held shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $13.79 on 2026-08-27.

Original reporting
SEC EDGAR · LEDERMAN SETH
Published Aug 31, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TNXP
Neutral
medium confidence
Mentioned
$TNXP
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNXPNeutralLow
01

Why it matters

The disclosed purchase is the first public report of this transaction.

02

Market read

Small insider buy, limited immediate market impact.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 4/10Novelty 5/10Timing: post‑market filing

Background

Form 4 filings disclose insider trades; investors watch CEO purchases for sentiment cues.

Company-level read

Ticker impact

$TNXPNeutralMedium confidence
Context

CEO Seth Lederman purchased 2,000 shares for $27,580, increasing his stake to 11,005 shares.

Expected impact

Limited short‑term price effect; may provide slight upside bias.

Evidence & confidence

A $28K buy by the CEO is a primary Form 4 disclosure, but the amount is small relative to market cap, so impact is likely minimal.

Market effects

Sector

None significant for the biotech sector.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • person
    Seth Lederman

    Chief Executive Officer of Tonix Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNXP insider trading history →

Related articles

AUG 24
$TNXPLow

Next-Generation Mpox Vaccine Shows Promise for Durable Protection and Future Outbreak Preparedness

Tonix Pharmaceuticals' TNX-801, an investigational mpox vaccine, showed promise in preclinical studies, offering durable immunity and potential advantages over existing vaccines. According to Sina Bavari, PhD, the vaccine demonstrated robust immune responses and protection in animal models. Tonix aims to address unmet needs in infectious disease preparedness, with TNX-801 being part of its broader biodefense strategy. The company highlights the importance of next-generation vaccines in preventin

infectioncontroltoday.com3 min
AUG 17
$TNXPMedAI 8/10

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.

fool.com6 min
AUG 10
$TNXPMedAI 8/10

Tonix Pharmaceuticals Holding Corp. (TNXP): Results of Operations and Financial Condition

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, no

SEC EDGAR 8-K7 min
AUG 10
$TNXPMedAI 8/10

Tonix's Fibromyalgia Treatment Reaches 136M Covered Lives

Tonix Pharmaceuticals (Nasdaq: TNXP) reported Q2 2026 net product revenue of about $13.5M, up from $2.0M a year earlier, driven by TONMYA sales of about $11.0M and migraine products Zembrace SymTouch and Tosymra. TONMYA prescriptions rose to 12,592 and coverage expanded to ~136M lives. Cash was ~$176.2M at June 30, 2026; net loss was $40.6M.

stocktitan.net6 min